Drug intelligence / Profile preview

BMS-943539

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

BMS-943539 is an investigational biologic developed by Bristol Myers Squibb. It belongs to the Adnectin class, which are targeted biologics derived from the 10th type III domain of human fibronectin. BMS-943539 is specifically engineered to bind human serum albumin (HSA). This binding is intended to extend the circulating half-life of the molecule by utilizing the long serum half-life of albumin. It has been evaluated in a Phase 1 clinical trial in healthy male subjects to assess its pharmacokinetics and safety following intravenous administration.

Beyond the preview

Go deeper on BMS-943539.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-943539.

Explore the full profile